NewEdge Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

NewEdge Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.53K	Hold	78	–	–	﹤0.01%	3574
2026 Q1	$8.1K	Sell	78 -23	-23%	-$2.45K	﹤0.01%	3451
2025 Q4	$10.4K	Sell	101 -1	-1%	-$97	﹤0.01%	3461
2025 Q3	$9.22K	Hold	102	–	–	﹤0.01%	3352
2025 Q2	$8.97K	Sell	102 -8,771	-99%	-$760K	﹤0.01%	3246
2025 Q1	$809K	Buy	8,873 +607	+7%	+$54.7K	﹤0.01%	1305
2024 Q4	$713K	Buy	8,266 +621	+8%	+$56.2K	﹤0.01%	1343
2024 Q3	$726K	Buy	7,645 +3,092	+68%	+$294K	﹤0.01%	1256
2024 Q2	$417K	Buy	4,553 +377	+9%	+$33.7K	﹤0.01%	1524
2024 Q1	$379K	Buy	+4,176	New	+$366K	﹤0.01%	1512
2023 Q1	–	Sell	-281	Closed	-$21.9K	–	3960
2022 Q4	$21.9K	Buy	+281	New	+$20.7K	﹤0.01%	2093

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

NewEdge Advisors's PPH Position: Q2 2026 in Review

NewEdge Advisors held its VanEck Pharmaceutical ETF (PPH) position steady in Q2 2026 at 78 shares worth $8.53K. The position accounts for ﹤0.01% of the portfolio, ranked #3574.

NewEdge Advisors first reported a position in PPH in Q4 2022 and has held it in 11 quarters since. The position peaked at $809K in Q1 2025. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

NewEdge Advisors held 78 shares of VanEck Pharmaceutical ETF worth $8.53K as of Q2 2026.
NewEdge Advisors left its VanEck Pharmaceutical ETF share count unchanged in Q2 2026.
VanEck Pharmaceutical ETF made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3574 holding.
NewEdge Advisors first reported a position in VanEck Pharmaceutical ETF in Q4 2022 and has held it in 11 quarters since.
NewEdge Advisors's VanEck Pharmaceutical ETF position peaked at $809K in Q1 2025.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.